Justin Kim
Stock Analyst at Oppenheimer
(0)
# 4195
Out of 5,218 analysts
43
Total ratings
44.83%
Success rate
-6.31%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Apellis Pharmaceutic... | Maintains: Outperform | 65 40 | 33.24 | 20.34% | 6 | Nov 6, 2024 | |
Pharvaris | Maintains: Outperform | 38 42 | 18.51 | 126.9% | 4 | Sep 6, 2024 | |
Cytokinetics | Maintains: Outperform | 107 106 | 48.66 | 117.84% | 5 | May 9, 2024 | |
Immunocore Hldgs | Reiterates: Outperform | 85 87 | 28.93 | 200.73% | 5 | Feb 29, 2024 | |
Vera Therapeutics | Initiates Coverage On: Outperform | 26 | 44 | -40.91% | 1 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Perform | n/a | n/a | n/a | 2 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 17 | 2.29 | 642.36% | 1 | Aug 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 33 34 | n/a | n/a | 2 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 14 18 | n/a | n/a | 3 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Perform | n/a | n/a | n/a | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Perform | n/a | n/a | n/a | 4 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 59 | 36.62 | 61.11% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Perform | n/a | n/a | n/a | 3 | Jun 30, 2022 |